The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamicacid in human colon adenocarcinoma HT-29 cells

International Journal of Oncology

Volumn 33, Issue 2, 2008, Pages 325-331

  Portanova, Patrizia ^a   Russo, Tiziana ^a   Pellerito, Ornella ^a   Calvaruso, Giuseppe ^a   Giuliano, Michela ^a   Vento, Renza ^a   Tesoriere, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Apoptosis; Colon adenocarcinoma; Oxidative stress; Suberoylanilide hydroxamic acid

Indexed keywords

ACETYLCYSTEINE; CASPASE; CASPASE 8; DEATH RECEPTOR 5; DIPHENYLIODONIUM SALT; FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE INHIBITOR; PROTEIN BID; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HT29; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ADENOCARCINOMA; ANTIOXIDANTS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL SURVIVAL; COLONIC NEOPLASMS; ENZYME ACTIVATION; ENZYME INHIBITORS; HISTONE DEACETYLASES; HT29 CELLS; HUMANS; HYDROXAMIC ACIDS; MEMBRANE POTENTIAL, MITOCHONDRIAL; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 48749090017     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000012     Document Type: Article

References (35)

1. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389: 349-352, 1997.
2. Carey N and La Thangue NB: Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol 6: 369-375, 2006.
3. Santini V, Gozzini A and Ferrari G: Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 8: 383-393, 2007.
4. Kim TY, Bang YJ and Robertson KD: Histone deacetylase inhibitors for cancer therapy. Epigenetics 1: 14-23, 2006.
5. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001.
6. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB and Grant S: Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18: 7016-7025, 1999.
7. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA and Richon VM: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170, 2000.
8. Richon VM, Sandhoff TW, Rifkind RA and Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019, 2000.
9. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM and Frankel SR: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39, 2007.
10. Sonnemann J, Dreyer L, Hartwig M, Palani CD, Hong le TT, Klier U, Bröker B, Völker U and Beck JF: Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol 133: 847-858, 2007.
11. Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD and Srivastava RK: Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 16: 1125-1138, 2005.
12. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM and Munster PN: Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92: 223-237, 2004.
13. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y and Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300, 2003.
14. + cells sensitive and resistant to STI571. Blood 102: 3765-3774, 2003.
15. Emanuele S, Lauricella M, Carlisi D, Vassallo B, D'Anneo A, Di Fazio P, Vento R and Tesoriere G: SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 12: 1327-1338, 2007.
16. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007.
17. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS and Wolmark N: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25: 2198-2004, 2007.
18. Kwon HC, Oh SY, Lee S, Kim SH and Kim HJ: Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study. World J Gastroenterol 13: 6231-6235, 2007.
19. Longley DB, Allen WL and Johnston PG: Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 1766: 184-196, 2006.
20. Park Y, Hunter DJ, Spiegelman D, Bergkvist L, Berrino F, van den Brandt PA, Buring JE, Colditz GA, Freudenheim JL, Fuchs CS, Giovannucci E, Goldbohm RA, Graham S, Harnack L, Hartman AM, Jacobs DR Jr, Kato I, Krogh V, Leitzmann MF, McCullough ML, Miller AB, Pietinen P, Rohan TE, Schatzkin A, Willett WC, Wolk A, Zeleniuch-Jacquotte A, Zhang SM and Smith-Warner SA: Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA 294: 2849-2857, 2005.
21. Lim CC, Ferguson LR and Tannock GW: Dietary fibres as 'prebiotics': implications for colorectal cancer. Mol Nutr Food Res 49: 609-619, 2005.
22. Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, Fodstad Ø and Ree AH: Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol 1: 25, 2006.
23. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P and Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808, 1992.
24. Lauricella M, Calvaruso G, Carabillò M, D'Anneo A, Giuliano M, Emanuele S, Vento R and Tesoriere G: pRb suppresses camptothecin-induced apoptosis in human osteosarcoma Saos-2 cells by inhibiting c-Jun N-terminal kinase. FEBS Lett 499: 191-197, 2001.
25. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ and Johnstone RW: The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98: 10833-10838, 2001.
26. Malik F, Kumar A, Bhushan S, Khan S, Bhatia A, Suri KA, Qazi GN and Singh J: Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine. Apoptosis 12: 2115-2133, 2007.
27. Krueger A, Schmitz I, Baumann S, Krammer PH and Kirchhoff S: Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 276: 20633-20640, 2001.
28. Kuo PL, Chen CY and Hsu YL: Isoobtusilactone A induces cell cycle arrest and apoptosis through reactive oxygen species/apoptosis signal-regulating kinase 1 signaling pathway in human breast cancer cells. Cancer Res 67: 7406-7420, 2007.
29. Henderson BR and Fagotto F: The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep 3: 834-839, 2002.
30. Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9: 59-71, 2005.
31. Wang J, Li L, Cang H, Shi G and Yi J: NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells. Leuk Res 32: 429-436, 2008.
32. Seo SK, Lee HC, Woo SH, Jin HO, Yoo DH, Lee SJ, An S, Choe TB, Park MJ, Hong SI, Park IC and Rhee CH: Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction. Apoptosis 12: 195-209, 2007.
33. Reddy RM, Yeow WS, Chua A, Nguyen DM, Baras A, Ziauddin MF, Shamimi-Noori SM, Maxhimer JB, Schrump DS and Nguyen DM: Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade. Apoptosis 12: 55-71, 2007.
34. Baskin-Bey ES and Gores GJ: Death by association: BH3 domain-only proteins and liver injury. Am J Physiol Gastrointest Liver Physiol 289: G987-G990, 2005.
35. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G and Ahnen DJ: Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2: 885-892, 2003.